Twelve weeks with retinaldehyde: reading the data.

The Forté trial started with 42 volunteers across Fitzpatrick II to VI. Everyone was baselined for fine line depth, evenness of tone, and self-reported tolerance. Application: three drops on clean, dry skin at night, building from every third night to nightly across three weeks.

At day thirty, self-reported tolerance was already the metric to watch. Ninety-three percent of the cohort had made it to nightly application without a retinisation window. At day sixty, fine line reduction was averaging seventeen percent. At day ninety, thirty-four percent. Even tone tracked at forty-one percent by the twelve-week mark.

That is what encapsulation buys you: not a bigger number, a steadier curve.

Read next

Time-release actives: the case for less, applied slower.

The area under the curve is what determines the clinical effect. Peak concentration is what determines the sting.